Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Accumulated Expenses (2021 - 2025)

Verrica Pharmaceuticals has reported Accumulated Expenses over the past 5 years, most recently at $12.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $12.8 million for Q4 2025, down 4.99% from a year ago — trailing twelve months through Dec 2025 was $12.8 million (down 4.99% YoY), and the annual figure for FY2025 was $12.8 million, down 4.99%.
  • Accumulated Expenses for Q4 2025 was $12.8 million at Verrica Pharmaceuticals, up from $12.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for VRCA hit a ceiling of $18.9 million in Q3 2024 and a floor of $242000.0 in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $9.1 million (2023), compared with a mean of $8.2 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 73.29% in 2023 and later soared 2842.01% in 2024.
  • Verrica Pharmaceuticals' Accumulated Expenses stood at $3.3 million in 2021, then decreased by 18.71% to $2.7 million in 2022, then soared by 422.03% to $13.9 million in 2023, then dropped by 2.52% to $13.5 million in 2024, then dropped by 4.99% to $12.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $12.8 million (Q4 2025), $12.6 million (Q3 2025), and $13.1 million (Q2 2025) per Business Quant data.